The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer

Massimo Maffezzini, Giacomo Capponi, Stefania Casazza, Fabio Campodonico, Roberto Bandelloni, Matteo Puntoni

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1 %), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.

Original languageEnglish
Pages (from-to)127-131
Number of pages5
JournalArchivio Italiano di Urologia e Andrologia
Volume80
Issue number4
Publication statusPublished - Dec 2008

Fingerprint

Urinary Bladder Neoplasms
Cell Biology
Recurrence
Cystoscopy
Carcinoma in Situ
Fluorescence In Situ Hybridization
Chromosome Aberrations
Disease Progression

Keywords

  • Fluorescence in situ hybridization
  • Non-muscle invasive bladder cancer
  • Progression
  • Recurrence
  • Urinary cytology

ASJC Scopus subject areas

  • Urology

Cite this

Maffezzini, M., Capponi, G., Casazza, S., Campodonico, F., Bandelloni, R., & Puntoni, M. (2008). The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer. Archivio Italiano di Urologia e Andrologia, 80(4), 127-131.

The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer. / Maffezzini, Massimo; Capponi, Giacomo; Casazza, Stefania; Campodonico, Fabio; Bandelloni, Roberto; Puntoni, Matteo.

In: Archivio Italiano di Urologia e Andrologia, Vol. 80, No. 4, 12.2008, p. 127-131.

Research output: Contribution to journalArticle

Maffezzini, M, Capponi, G, Casazza, S, Campodonico, F, Bandelloni, R & Puntoni, M 2008, 'The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer', Archivio Italiano di Urologia e Andrologia, vol. 80, no. 4, pp. 127-131.
Maffezzini, Massimo ; Capponi, Giacomo ; Casazza, Stefania ; Campodonico, Fabio ; Bandelloni, Roberto ; Puntoni, Matteo. / The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer. In: Archivio Italiano di Urologia e Andrologia. 2008 ; Vol. 80, No. 4. pp. 127-131.
@article{9e55df13a8d6494793a895eaf7b75ad6,
title = "The Urovysion{\circledR} F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer",
abstract = "Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6{\%}). In this group 42 (72.6{\%}) and 27 (46.6{\%}) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8{\%}) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4{\%}) and 8 (47.1 {\%}), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.",
keywords = "Fluorescence in situ hybridization, Non-muscle invasive bladder cancer, Progression, Recurrence, Urinary cytology",
author = "Massimo Maffezzini and Giacomo Capponi and Stefania Casazza and Fabio Campodonico and Roberto Bandelloni and Matteo Puntoni",
year = "2008",
month = "12",
language = "English",
volume = "80",
pages = "127--131",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "4",

}

TY - JOUR

T1 - The Urovysion® F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer

AU - Maffezzini, Massimo

AU - Capponi, Giacomo

AU - Casazza, Stefania

AU - Campodonico, Fabio

AU - Bandelloni, Roberto

AU - Puntoni, Matteo

PY - 2008/12

Y1 - 2008/12

N2 - Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1 %), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.

AB - Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1 %), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.

KW - Fluorescence in situ hybridization

KW - Non-muscle invasive bladder cancer

KW - Progression

KW - Recurrence

KW - Urinary cytology

UR - http://www.scopus.com/inward/record.url?scp=58849129111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849129111&partnerID=8YFLogxK

M3 - Article

C2 - 19235427

AN - SCOPUS:58849129111

VL - 80

SP - 127

EP - 131

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 4

ER -